sábado, 14 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 3, 2026

New Crypto Pepeto Binance Listing Update Following Shiba Inu Success and Cardano Price Prediction Target

View original at globenewswire.com
New Crypto Pepeto Binance Listing Update Following Shiba Inu Success and Cardano Price Prediction Target Dubai, UAE, April 02, 2026 (GLOBE NEWSWIRE) -- The new crypto Pepeto just appeared on CoinMarketCap with a live token page, a move that historically signals an exchange listing is days away from going public…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ADA will trade between $0.24 and $0.42 through 2026, with algorithm projecting ADA never reclaiming its all-time high, capping highest estimated price at $0.63 as far out as 2047

    60% confidence
  • ADA bullish case only reaches $3.25 for the full year, assuming conditions Cardano has consistently failed to produce

    60% confidence
  • A pair of brothers in New York put $8,000 into Shiba Inu before anyone outside crypto circles had heard of it, and six months later that position was worth $9 million

    60% confidence
  • ADA will reach an upside of just $0.57 for 2026 and $1.89 by 2030

    60% confidence

Data points we hold from this source

Pepeto · capital raised8.6 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com
New Crypto Pepeto Binance Listing Update Following Shiba Inu Success and Cardano Price Prediction Target — Source | Via News | es.VIA.NEWS